CA2473802A1 - Engineering absorption of therapeutic compounds via colonic transporters - Google Patents

Engineering absorption of therapeutic compounds via colonic transporters Download PDF

Info

Publication number
CA2473802A1
CA2473802A1 CA002473802A CA2473802A CA2473802A1 CA 2473802 A1 CA2473802 A1 CA 2473802A1 CA 002473802 A CA002473802 A CA 002473802A CA 2473802 A CA2473802 A CA 2473802A CA 2473802 A1 CA2473802 A1 CA 2473802A1
Authority
CA
Canada
Prior art keywords
conjugate
transporter
agent
human
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002473802A
Other languages
English (en)
French (fr)
Inventor
Noa Zerangue
Kenneth C. Cundy
Mark A. Gallop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XenoPort Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2473802A1 publication Critical patent/CA2473802A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002473802A 2002-01-24 2003-01-24 Engineering absorption of therapeutic compounds via colonic transporters Abandoned CA2473802A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35180802P 2002-01-24 2002-01-24
US60/351,808 2002-01-24
US10/351,291 US20030158254A1 (en) 2002-01-24 2003-01-23 Engineering absorption of therapeutic compounds via colonic transporters
US10/351,291 2003-01-23
PCT/US2003/002206 WO2003065982A2 (en) 2002-01-24 2003-01-24 Engineering absorption of therapeutic compounds via colonic transporters

Publications (1)

Publication Number Publication Date
CA2473802A1 true CA2473802A1 (en) 2003-08-14

Family

ID=27737413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002473802A Abandoned CA2473802A1 (en) 2002-01-24 2003-01-24 Engineering absorption of therapeutic compounds via colonic transporters

Country Status (7)

Country Link
US (1) US20030158254A1 (enExample)
EP (1) EP1575494A2 (enExample)
JP (1) JP2005529847A (enExample)
KR (1) KR20040111348A (enExample)
AU (1) AU2003244398A1 (enExample)
CA (1) CA2473802A1 (enExample)
WO (1) WO2003065982A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002310409C1 (en) * 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US7378239B2 (en) * 2002-06-25 2008-05-27 Index Diagnostics Ab Method of differentiating between ulcerative colitis and Crohn's disease
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US20050032135A1 (en) * 2003-07-03 2005-02-10 Xenoport, Inc. Monocarboxylate transporters expressed in cancer cells
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
RU2006118801A (ru) * 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
WO2005074996A2 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Lat1 transporter expressed in blood brain barrier cells
US7452680B2 (en) * 2004-01-30 2008-11-18 Xenoport, Inc. MCT1 transporters expressed in blood brain barrier cells
US20060003920A1 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. LAT1 transporters expressed in cancer cells
AU2005252220B2 (en) * 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20060003361A1 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. SMVT transporters expressed in cancer cells
WO2006001986A2 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. Glut3 transporters expressed in cancer cells
US20060003362A1 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. ENT1 transporters expressed in cancer cells
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7348276B2 (en) * 2005-03-30 2008-03-25 Fujitsu, Limited Fabrication process of semiconductor device and polishing method
CN101232868A (zh) * 2005-04-19 2008-07-30 阿尔扎公司 曲马多和加巴喷丁的控释递药剂型
US7241805B2 (en) * 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
TW200843731A (en) * 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673336A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
TW200924746A (en) * 2007-09-07 2009-06-16 Xenoport Inc Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
CA2747253A1 (en) * 2007-12-20 2009-07-02 Index Diagnostics Ab Method and kit for use in the differentiation of ibd and ibs and further distinction between disease types of ibd
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
CA2789236C (en) 2009-11-09 2014-09-09 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2014113717A1 (en) 2013-01-18 2014-07-24 Ark Diagnostics, Inc. Voriconazole immunoassays
WO2014126861A1 (en) 2013-02-13 2014-08-21 Ark Diagnostics, Inc. Posaconazole immunoassays
CA3184236A1 (en) * 2020-07-01 2022-01-06 Tyler White Dietary composition and method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
ATE277739T1 (de) * 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells

Also Published As

Publication number Publication date
US20030158254A1 (en) 2003-08-21
KR20040111348A (ko) 2004-12-31
WO2003065982A2 (en) 2003-08-14
JP2005529847A (ja) 2005-10-06
AU2003244398A1 (en) 2003-09-02
WO2003065982A3 (en) 2005-12-08
EP1575494A2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
US20030158254A1 (en) Engineering absorption of therapeutic compounds via colonic transporters
US7919454B2 (en) Methods of treating using conjugates transported by a PEPT2 transporter
US7598235B2 (en) Bile-acid conjugates for providing sustained systemic concentrations of drugs
US20020098999A1 (en) Compounds for sustained release of orally delivered drugs
US7144877B2 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2002028882A1 (en) Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US6992076B2 (en) Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US7420002B2 (en) Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US20050070715A1 (en) Methods for synthesis of acyloxyalkyl compounds
US7053076B2 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US20040161424A1 (en) Human organic solute transporters
WO2004033655A2 (en) Human organic solute transporters
EP1343515A1 (en) Compounds for sustained release of orally delivered drugs

Legal Events

Date Code Title Description
FZDE Discontinued